Fougera Granted Approval to Market Generic Scalp Solution
Posted on: Wednesday, 7 May 2008, 12:01 CDT
Fougera, a division of Nycomed US, has received FDA approval to bring to market the first generic Calcipotriene Topical Solution 0.005%. The generic formulation compares to Dovonex by Warner-Chilcott.
Fougera's Calcipotriene Topical Solution (scalp solution) is indicated for the topical treatment of chronic, moderately severe psoriasis of the scalp. It is available in a 60ml bottle.
David Klaum, senior vice president, commercial business operations, Fougera, said: "Fougera has received more FDA approvals for topical products during the past seven years than any other generic company."
Source: Datamonitor
Related Articles
- FDA approves Pennsaid(R) Topical Solution
- FDA extends review of Pennsaid(R) diclofenac sodium topical solution
- Study Shows Nonprescription LCD Topical Solution is More Effective than Prescription-Strength Calcipotriol Cream for Moderate Plaque Psoriasis
- FDA OKs Novel Surgical Clotting Solution
- Taro Receives FDA Approval for Ciclopirox and Loratadine Syrup
- Hi-Tech Pharmacal Receives Approval for Ciclopirox Topical Solution
- Auriga Laboratories Announces the Formation of A.T.S. Pharmaceuticals, a Specialty Division Dedicated to Dermatology and Gastroenterology
- Barrier Therapeutics Receives FDA Approval for Solage(R) Topical Solution Labeling Expansion
- Hi-Tech Pharmacal Receives Tentative Approval for Calcipotriene Topical Solution
Rating: 2.6 / 5 (10 votes)
 |
 |
Rate this article:
User Comments (0)
RSS Feeds